Short-Schedule Intravesical Gemcitabine with Ablative Intent in Recurrent Ta-T1, G1-G2, Low- or Intermediate-Risk, Transitional Cell Carcinoma of the Bladder

European Urology

Volumn 51, Issue 4, 2007, Pages 956-961

  Maffezzini, Massimo ^a   Campodonico, Fabio ^a   Canepa, Giorgio ^a   Capponi, Giacomo ^a   Fontana, Vincenzo ^b  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Intravesical gemcitabine; Short schedule; Superficial bladder cancer

Indexed keywords

GEMCITABINE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIDE EFFECT; SKIN ULCER; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 33847092910     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.038     Document Type: Article

References (27)

1. Lee R., and Droller M. The natural history of bladder cancer: implications for therapy. Urol Clin North Am 27 (2000) 1-13
2. Kiemeney L.A., Witjes J.A., Heijbroek R.P., Verbeek A.L., and Debuyne F.M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150 (1993) 60-64
3. Parmar M.K.B., Freedman L.S., Hargreave T.B., and Tolley D.A. Prognostic factors for recurrence follow-up policies in treatment of superficial bladder cancer: report from British Medical Research Council Subgroup on superficial bladder cancer. J Urol 142 (1989) 284-288
4. Maffezzini M., Audisio R., Pavone-Macaluso M., and Hall R.R. Bladder cancer. Crit Rev Oncol Hematol 27 (1998) 151-153
5. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
6. Sylvester R.J., van der Meijden A.P.M., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
7. Oosterlinck W., Lobel B., Jakse G., Malmström P.U., Stöckle M., and Sternberg C. Guidelines on bladder cancer. European Association of Urology (EAU) Working Group on Oncological Urology. Eur Urol 41 (2002) 105-112
8. Stadler W.M., Kuzel T., Roth B., Raghavan D., and Dorr F.A. Phase II study of gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15 (1997) 3394-3398
9. Lorusso V., Pollera C.F., Antimi M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34 (1998) 1208-1212
10. Moore M.J., Tannock I.F., Ernst D.S., Huan S., and Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15 (1997) 3441-3445
11. Von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin, methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
12. Kilani R.T., Tamini Y., Karmali S., et al. Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs 13 (2002) 557-566
13. Shipley L.A., Brown T.J., Cornpropst J.D., Hamilton M., Daniels W.D., and Culp H.W. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats and dogs. Drug Metab Dispos 20 (1992) 849-855
14. Cozzi P.J., Bajorin D.F., Tong W., et al. Toxicology an pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5 (1999) 2629-2637
15. Witjes J.A., Vriesema J.L.J., van der Heijden A.G., Peters G.J., and Shalken J.A. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur Urol 44 (2003) 615-619
16. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical Gemcitabine in bacillus Calmette-Guerin refractory transitional cell carcinoma of the bladder. J Clin Oncol 20 (2002) 3193-3198
17. Laufer M., Ramalingam S., Shoenberg M.P., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21 (2003) 697-703
18. De Berardinis E., Antonini G., Peters G.J., et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 93 (2004) 491-494
19. Lamm D.L., van der Meijden A.P., Akaza H., et al. Intravesical chemo-and immunotherapy: How do we assess their effectiveness and what are their limitations and uses. Proceedings of the Fourth International Bladder Cancer Consensus Conference. Int J Urol 2 (1995) 23-35
20. Van der Meijden A.P., Hall R.R., Pavone-Macaluso M., Pawinsky A., Sylvester R., and Van Glabbeke M. Marker tumour response to the sequential combination of intravesical therapy with mitomycin C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organization for Research and Treatment on Cancer Genitourinary Group (EORTC 30897). Eur Urol 29 (1996) 199-203
21. Van der Meijden A.P., Hall R.R., Kurth K.H., Bouffioux C., and Sylvester R. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept [review]. Br J Urol 77 (1996) 634-637
22. Bono A.V., Hall R.R., Denis L., Lovisolo J.A., and Sylvester R. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol 29 (1996) 385-390
23. Mack D., Holtl W., Bassi P., et al., European Organization for Research and Treatment of Cancer Genitourinary Group. The ablative effect of quarter dose BCG on a papillary marker lesion of the bladder. J Urol 165 (2001) 401-403
24. Campodonico F., Canepa G., Capponi G., Bozzo L., and Maffezzini M. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 25 (2005) 2381-2384
25. Maffezzini M., Simonato A., Zanon M., Raber M., and Carmignani G. Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. J Urol 155 (1996) 91-93
26. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46 (2004) 339-343
27. Serretta V., Galuffo A., Pavone C., Allegro R., and Pavone-Macaluso M. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology 65 (2005) 65-69